JEAN LOUIS P.
- Country
- France
- Department
- Hopital Arnaud de Villeneuve( #1)
Research Overview
- A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25%
- Phase 2 Multicenter Randomized Open-label Study of Ifinatamab Deruxtecan in Pretreated Extensive-stage Small Cell Lung Cancer
- Phase 3 Randomized Study of Sacituzumab Govitecan vs. Docetaxel in Advanced/Metastatic NSCLC Post-Platinum Chemotherapy and Anti-PD-1/PD-L1 Therapy
Data & Insights
Has run more than one trial at 92 of 266 partner sites.
Specializations
Non-Small Cell Lung Cancer
The investigator demonstrates significant expertise in treating advanced and metastatic non-small cell lung cancer (NSCLC), with particular focus on various therapeutic approaches including immunotherapy combinations and targeted treatments.
- Stage IV NSCLC management
- Resectable Stage II-IIIB NSCLC
- MET-altered NSCLC variants
The research extends to CEACAM5-positive metastatic non-squamous NSCLC and cases without actionable genomic alterations.
Small Cell Lung Cancer
The investigator specializes in both limited-stage small cell lung cancer (LS-SCLC) and extensive-stage small cell lung cancer (ES-SCLC) treatment approaches.
- Post-chemoradiotherapy consolidation therapy
- Relapsed SCLC management
- Pretreated ES-SCLC interventions
Research interests include novel therapeutic strategies for both early-stage and advanced disease states.
Therapeutic Approaches
The investigator explores various innovative treatment modalities in lung cancer therapy.
- Immunotherapy combinations
- Targeted antibody-drug conjugates
- Combination chemotherapy regimens
- Post-surgical therapeutic interventions
Focus includes consolidation therapy and neoadjuvant treatment approaches for various lung cancer stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.